1.55% +0.009

Alzamend Neuro Inc (ALZN)

Alzamend Neuro Inc Borsa (ALZN) Ultime notizie

Alzamend Neuro Inc (ALZN)

Alzamend Neuro Inc Borsa (ALZN) Ultime notizie

Stock Performance Spotlight: Alzamend Neuro Inc (ALZN) Ends the Day at 0.58, Up by 0.57 – DWinneX - The Dwinnex

Alzamend Neuro secures Nasdaq listing extension - Investing.com India

Alzamend Neuro secures Nasdaq listing extension By Investing.com - Investing.com

Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel - Yahoo Finance UK

Analyzing Structure Therapeutics (NASDAQ:GPCR) & Alzamend Neuro (NASDAQ:ALZN) - Defense World

Alzamend Neuro Unveils Updated Investor Presentation Outlook - TipRanks.com - TipRanks

A Guide To The Risks Of Investing In Alzamend Neuro Inc (ALZN) – Knox Daily - Knox Daily

Alzamend Neuro Announces Initial Closing of Private Placement - Business Wire

Alzamend Neuro Announces Initial Closing of Private Placement - Investing News Network

Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Up 55.2% in April - Defense World

Alzamend Neuro Secures Strategic $25M Investment Deal - TipRanks.com - TipRanks

Tech IPO market still dead - AOL

Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an ... - Business Wire

EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares - Alzamend Neuro - Benzinga

EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares - Yahoo Finance

Alzamend Neuro halts its equity offering program By Investing.com - Investing.com

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program - Business Wire

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program - Business Wire

Alzamend Neuro And 2 Other Stocks Under $5 Insiders Are Buying - Alzamend Neuro (NASDAQ:ALZN), Mobile Inf - Benzinga

Alzamend Neuro director buys $688 worth of shares By Investing.com - Investing.com

Alzamend Neuro director buys $688 worth of shares By Investing.com - Investing.com

Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying

Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying - Aldeyra Therapeutics (NASDAQ:ALDX) - Benzinga

Alzamend Neuro director Milton Ault III buys $304 in shares By Investing.com - Investing.com

Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying

Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying - Alzamend Neuro (NASDAQ:ALZN), Anitra (AMEX: - Benzinga

Alzamend Neuro director Milton Ault III acquires $936k in company stock By Investing.com - Investing.com

Alzamend Neuro Secures Funding Through Preferred Stock Sale - TipRanks.com - TipRanks

Alzamend Neuro And 3 Other Stocks Under $3 Insiders Are Buying

Alzamend Neuro And 3 Other Stocks Under $3 Insiders Are Buying - Alzamend Neuro (NASDAQ:ALZN), Fortress B - Benzinga

Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next ... - Yahoo Finance

Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next ... - Business Wire

Alzamend Neuro regains compliance with Nasdaq bid price rule - Investing.com India

Alzamend Neuro Announces Reverse Stock Split - Business Wire

EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder - Yahoo Finance

Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued ... - Business Wire

Alzamend targets Phase IIa trial for bipolar treatment candidate - Clinical Trials Arena

We're A Little Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate - Yahoo Finance

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans? - Simply Wall St

Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001 - Business Wire

3 Biotech Stocks That Could Turn $1000 into $10000 by 2024 - InvestorPlace

3 Penny Stocks That Could Turn $1000 into $10000 in a Year - InvestorPlace

Alzamend pushing ahead with Alzheimer's vaccine trial - Labiotech.eu

Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for ... - Business Wire

Alzamend and Biorasi to partner for trial of ALZN002 for Alzheimer's - Clinical Trials Arena

EXCLUSIVE: Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementia - Benzinga

SEC Goes After 'MrZackMorris,' 'Stock Sniper' For Alleged Fraud - ABVC BioPharma (NASDAQ:ABVC), Alzamend - Benzinga

10 Biotech Stocks With The Biggest Upside - Yahoo Finance

Alzamend Seeks FDA Approval to Test ALZN002 Vaccine for... - Alzheimer's News Today

Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer's ... - Business Wire

Simile a ALZN